SCHEMBL7777307

SCHEMBL7777307

COc1ccc(-c2cc(OC)ccc2Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.50
ABCB1 P08183 1/20 0.50
BCR P11274 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
BACE1 P56817 3/20 0.44
MAOB P27338 1/20 0.44
GSTP1 P09211 1/20 0.44
ESR2 Q92731 2/20 0.44
ESR1 P03372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30610973 0.92 HDAC3 (0.51) ABL1ABCB1BCRSMN1; SMN2KDM4E
SCHEMBL7778332 0.89 ESR2 (0.57) ABL1ABCB1BCRSMN1; SMN2KDM4E
SCHEMBL9912737 0.89 MAPT (0.47) KDM4EMAOBNPC1RAB9AALDH1A1
SCHEMBL30610959 0.89 MAPT (0.47) KDM4EMAOBNPC1RAB9AALDH1A1
SCHEMBL2722749 0.88 PTPN1 (0.53) ABL1ABCB1BCRSMN1; SMN2KDM4E
SCHEMBL6449465 0.87 CA1 (0.48) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL7693920 0.86 ABL1 (0.42) ABL1ABCB1BCRSMN1; SMN2KDM4E
SCHEMBL7777345 0.85 ESR2 (0.57) ABL1ABCB1BCRSMN1; SMN2KDM4E
SCHEMBL7775889 0.83 BACE1 (0.58) SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL5858581 0.82 CYP1A1 (0.53) ABL1ABCB1BCRSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1121125-A1 PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME ELI LILLY AND COMPANY (US) 2001-08-08 EP claimed
WO-2000021535-A1 PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME ELI LILLY AND COMPANY (US) 2000-04-20 WO claimed
EP-2958907-B1 BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS NOVARTIS AG (CH) 2018-02-28 EP disclosed